Michael Schmidt's questions to Urogen Pharma Ltd (URGN) leadership • Q4 2024
Question
Michael Schmidt of Guggenheim inquired about the expected initial launch trajectory for UGN-102, potential pricing relative to JELMYTO, and whether to anticipate a significant channel inventory build.
Answer
Chief Commercial Officer David Lin stated that the launch curve for UGN-102 is expected to be similar in shape to JELMYTO's, but with larger absolute numbers due to the larger patient population. He noted that pricing is currently being evaluated in the $18,000 to $19,000 per dose range, with ongoing payer research to refine this figure.